|Table of Contents|

Review of influencing factors and mechanisms of EGFR-TKIs-associated rash in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 24
Page:
4663-4673
Research Field:
Publishing date:

Info

Title:
Review of influencing factors and mechanisms of EGFR-TKIs-associated rash in non-small cell lung cancer
Author(s):
SONG Shanshan; JIANG Fusheng; WANG Liang; HUANG Bozhen; LIU Xinxin; JIANG Min
Beijing Shijitan Hospital,Capital Medical University，Beijing 100038，China.
Keywords:
non-small cell lung cancer; targeted therapy; EGFR-TKIs; rash; mechanism
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.24.013
Abstract:
Non-small cell lung cancer (NSCLC) is the most frequent malignant tumor in China.Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of driver gene EGFR mutation-positive NSCLC,and they are currently the first-line standard treatment option for EGFR-mutated advanced NSCLC.However,rash is the most common adverse reaction during oral administration of EGFR-TKIs.The discomfort and change in appearance caused by rash is one of the most important causes of treatment reduction or interruption,which affects the adherence to targeted therapy.Dermatotoxic reactions make patients feel apprehensive,frustrated and depressed due to dermatologic symptoms,affecting their social activities,and social isolation can lead to episodes of depression or worsening of the primary disease,which can affect the patient's quality of life,and consequently,the treatment of the primary disease.Therefore,the aim of this paper is to enhance the understanding and judgment of drug-associated rash by reviewing the influencing factors and mechanisms of EGFR-TKIs-associated rash,to help the early diagnosis and correct management of drug-associated rash in clinical practice,and to guide the future diagnosis and treatment based on the mechanism,so as to improve the quality of life of patients.

References:

［1］中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南［M］.北京:人民卫生出版社,2024:49. The Chinese Society of Clinical Oncology.Guidelines of Chinese Society of Clinical Oncology non-small cell lung cancer［M］.Beijing:People's Medical Publishing House,2024:49.
［2］中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)小细胞肺癌诊疗指南［M］.北京:人民卫生出版社,2024:11. The Chinese Society of Clinical Oncology.Guidelines of Chinese Society of Clinical Oncology small cell lung cancer［M］.Beijing:People's Medical Publishing House,2024:11.
［3］LI WH,GUO L,LIU YT,et al.Potential unreliability of uncommon ALK,ROS1,and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC［J］.J Thorac Oncol,2021,16(3):404-418.
［4］LI T,PEREZ-SOLER R.Skin toxicities associated with epidermal growth factor receptor inhibitors［J］.Target Oncol,2009,4(2):107-119.
［5］LACOUTURE ME.Mechanisms of cutaneous toxicities to EGFR inhibitors［J］.Nat Rev Cancer,2006,6(10):803-812.
［6］胡洁,林丽珠,骆肖群,等.EGFR-TKI不良反应管理专家共识［J］.中国肺癌杂志,2019,22(02):57-81. HU J,LIN LZ,LUO XQ,et al.Expert consensus on the management of adverse reactions to EGFR-TKI［J］.Chinese Journal of Lung Cancer,2019,22(02):57-81.
［7］SHI Y,LI J,ZHANG S,et al.Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma Histology-Mainland China subset analysis of the PIONEER study［J］.PLoS One,2015,10(11):e0143515.
［8］PETROS WP,YOUNIS IR,FORD JN,et al.Effects of tobacco smoking and nicotine on cancer treatment［J］.Pharmacotherapy,2012,32(10):920-931.
［9］HAMILTON M,WOLF JL,RUSK J,et al.Effects of smoking on the pharmacokinetics of erlotinib［J］.Clin Cancer Res,2006,12(7Pt1):2166-2171.
［10］LU JF,EPPLER SM,WOLF J,et al.Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer［J］.Clin Pharmacol Ther,2006,80(2):136-145.
［11］AMADOR ML,OPPENHEIMER D,PEREA S,et al.An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors［J］.Cancer Res,2004,64(24):9139-9143.
［12］ETIENNE-GRIMALDI MC,PEREIRA S,MAGNE N,et al.Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients［J］.Ann Oncol,2005,16(6):934-941.
［13］JATOI A,THROWER A,SLOAN JA,et al.Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)［J］.Oncologist,2010,15(9):1016-1022.
［14］BRONTE G,ROLFO C,GIOVANNETTI E,et al.Are erlotinib and gefitinib interchangeable,opposite or complementary for non-small cell lung cancer treatment? Biological,pharmacological and clinical aspects［J］.Crit Rev Oncol Hematol,2014,89:300-313.
［15］MODJTAHEDI H,CHO BC,MICHEL MC,et al.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer［J］.Naunyn Schmiedebergs Arch Pharmacol,2014,387:505-521.
［16］BUROTTO M,MANASANCH EE,WILKERSON J,et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer:A meta-analysis of toxicity and efficacy of randomized clinical trials［J］.The Oncologist,2015,20:400-410.
［17］HASPINGER ER,AGUSTONI F,TORRI V,et al.Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations［J］.Crit Rev Oncol Hematol,2015,94:213-227.
［18］WU PA,BALAGULA Y,LACOUTURE ME,et al.Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors［J］.Curr Opin Oncol,2011,23:343-351.
［19］IWASAKU M,UCHINO J,YAMADA T,et al.Rationale and design of a phase II study to evalu ate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epiderm al growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)［J］.Transl Lung Cancer Res,2019,8(4):519-523．
［20］AW DC,TAN EH,CHIN TM,et al.Management of epidermal growth fact or receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities［J］.Asia Pac J Clin Oncol,2018,14(1):23-31．
［21］YANG JC,AHN MJ,KIM DW,et al.Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer:AURA study phase II extension component［J］.J Clin Oncol,2017,35:1288-1296.
［22］REZAKOVIC'S,PA3TAR Z,BUKVIC'MOKOS Z,et al.Erlotinib-induced rosacea-like dermatitis［J］.Acta Dermatovenerol Croat,2016,24(1):65-69.
［23］CHU CY,CHEN KY,WEN-CHENG CHANG J,et al.Taiwanese dermatological association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities［J］.J For Mos Med Assoc,2017,116(6):413-423.
［24］INDINI A,PETRELLI F,TOMASELLO G,et al.Impact of use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes:a systematic review and meta-analysis［J］.Cancers(Basel),2020,12(4):998.
［25］KUMARAKULASINGHE NB,SYN N,SOON YY,et al.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC:a retrospective database analysis of potential drug interaction［J］.Oncotarget,2016,7(51):85542-85550.
［26］UCHIYAMA AAT,SILVA PAIA,LOPES MSM,et al.Proton pump inhibitors and oncologic treatment efficacy:a practical review of the literature for oncologists ［J］.Curr Oncol,2021,28(1):783-799.
［27］SINGH V,GOHIL N,RAMIREZ-GARCIA R.New insight into the control of peptic ulcer by targeting the histamine H2 receptor［J］.J Cell Biochem,2018,119(2):2003-2011.
［28］WHEATLEY-PRICE P,DING K,SEYMOUR L,et al.Erlotinib for advanced non-small-cell lung cancer in the elderly:an analysis of the National Cancer Institute of Canada clinical trials group study BR.21［J］.J Clin Oncol,2008,26(14):2350-2357.
［29］LI J,ZHAO M,HE P,et al.Differential metabolism of Gefitinib and Erlotinib by human cytochrome P450 enzymes［J］.Clin Cancer Res,2007,13(12):3731-3737.
［30］LIU X.Transporter-mediated drug-drug interactions and their significance［J］.Adv Exp Med Biol,2019,1141:241-291.
［31］LIN JH,YAMAZAKI M.Role of P-glycoprotein in pharmacokinetics:clinical implications ［J］.Clin Pharmacokinet,2003,42(1):59-98.
［32］ELMELIEGY M,VOURVAHIS M,GUO C,et al.Effect of p-glycoprotein(P-gp) inducers on exposure of P-gp substrates:review of clinical drug-drug interaction studies ［J］.Clin Pharmacokinet,2020,59(6):699-714.
［33］MAO Q,UNADKAT JD.Role of the breast cancer resistance protein(BCRP/ABCG2) in drug transport:an update ［J］.AAPS J,2015,17(1):65-82.
［34］HUANG LH,FU LW.Mechanisms of resistance to EGFR tyrosine kinase inhibitors［J］.Acta Pharm Sin B,2015,5(5):390-401.
［35］MALIK I,HECHT JR,PATNAIK A,et al.Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)［J］.J Clin Oncol,2005,23(6):3520.
［36］LING J,JOHNSON KA,MIAO Z,et al.Metabolism and excretion of ERLOTINIB,A small molecule inhibitor of epidermal growth factor receptor tyrosine kinase,in healthy male volunteers［J］.Drug Metab Dispos,2006,34(3):420-426.
［37］SOTANIEMI EA,ARRANTO AJ,PELKONEN O,et al.Age and cytochrome P450-linked drug metabolism in humans:an analysis of 226 subjects with equal histopathologic conditions［J］.Clin Pharmacol Ther,1997,61(3):331-339.
［38］LEE E,KIM S,LEE J,et al.Ethnic differences in objective and subjective skin irritation response:an international study［J］.Skin Res Technol,2014,20:265-269.
［39］BARTER ZE,TUCKER GT,ROWLAND-YEO K.Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling［J］.Clin Pharmacokinet,2013,52(12):1085-1100.
［40］YU H,SINGH BADHAN RK.The pharmacokinetics of Gefitinib in a Chinese cancer population group:a virtual clinical trials population study［J］.J Pharm Sci,2021,110(10):3507-3511.
［41］程艳芳,王艳娜,王慧,等.CYP3A4*18基因多态性与初治晚期NSCLC患者EGFR-TKI疗效及不良反应的相关性分析［J］.中国药房,2017,28(32):4465-4470. CHENG YY,WANG YN,WANG H,et al.Correlation analysis of CYP3A4*18 gene polymorphisms with EGFR-TKI efficacy and adverse reactions in patients with primary advanced NSCLC［J］.China Pharmacy,2017,28(32):4465-4470.
［42］陈丽鹃,俞婷婷,单莉,等.NSCLC患者CYP2D6基因多态性与吉非替尼不良反应相关性研究［J］.现代肿瘤医学,2021,29(2):248-253. CHEN LJ,YU TT,SAN L,et al.Study on the correlation between CYP2D6 gene polymorphism and gefitinib adverse reaction in NSCLC patients［J］.Modern Oncology,2021,29(2):248-253.
［43］FERGUSON KM.Structure-based view of epidermal growth factor receptor regulation［J/OL］.Annu Rev Biophys,2008,37:353-373［2021-12-01］.https://www.annualreviews.org/content/journals/10.1146/annurev.biophys.37.032807.125829.
［44］ROSKOSKI R.The ErbB/HER family of protein-tyrosine kinases and cancer［J/OL］.Pharmacol Res,2014,79:34-74［2021-12-01］.https://www.sciencedirect.com/science/article/pii/S1043661813001771.
［45］DUGGIRALA KB,LEE YJ,LEE K.Chronicles of EGFR tyrosine kinase inhibitors:targeting EGFR C797S containing triple mutations［J］.Biomol Ther,2022,30(1):19-27.
［46］YANO S,KONDO K,YAMAGUCHI M,et al.Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition［J］.Anticancer Res,2003,23(5A):3639-3650.
［47］HOLCMANN M,SIBILIA M.Mechanisms underlying skin disorders induced by EGFR inhibitors［J］.Mol Cell Oncol,2015,2(4):e1004969.
［48］VALLBOHMER D,ZHANG W,GORDON M,et al.Molecular determinants of Cetuximab efficacy［J］.J Clin Oncol,2005,23(15):3536-3544.
［49］PEREZ-SOLER R,DELORD JP,HALPERN A,et al.HER1/EGFR inhibitor-associated rash:future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum［J］.Oncologist,2005,10(5):345-356.
［50］TANAKA T,MATSUOKA M,SUTANI A,et al.Frequency of and variables associated with the EGFR mutation and its subtypes［J］.Int J Cancer Suppl,2010,126:651-655.
［51］KARI C,CHAN TOROCHA DE QUADROS M,UJCR R.Targeting the epidermal growth factor receptor in cancer:apoptosis takes center stage［J］.Cancer Res,2003,63:1-5.
［52］PASTORE S,LULLI D,GIROLOMONI G.Epidermal growth factor receptor signalling in keratinocyte biology:implications for skin toxicity of tyrosine kinase inhibitors［J］.Arch Toxicol,2014,88(6):1189-1203.
［53］LACOUTURE ME.Mechanisms of cutaneous toxicities to EGFR inhibitors［J］.Nat Rev Cancer,2006,6(10):803-812.
［54］HOLCMANN M,SIBILIA M.Mechanisms underlying skin disorders induced by EGFR inhibitors［J］.Mol Cell Oncol,2015,2(4):e1004969.
［55］IF CHARO,RM RANSOHOFF.The many roles of chemokines and chemokine receptors in inflammation［J］.N Engl J Med,2006,354(6):610-621.
［56］B HOMEY,H ALENIUS,A MULLER,et al.CCL27-CCR10 interactions regulate T cell-mediated skin inflammation［J］.Nat Med,2002,8(2):157-165.
［57］LICHTENBERGER BEATE M,GERBER PETER A,HOLCMANN MARTIN,et al.EpidermalEGFR controls cutaneous host defense and prevents inflammation［J］.Sci Transl Med,2013,5(199):199ra111.
［58］RODECK U.Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling［J］.J Cell Physiol,2009,218(1):32-34.
［59］SURGULADZE D,DEEVI D,CLAROS N,et al.Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice［J］.Cancer Res,2009,69(14):5643-5647.
［60］BYRNE,SCOTT NAPIER.The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation［J］.Am J Pathol,2011,179(1):211-222.
［61］MASCIA F,LAM G,KEITH C,et al.Genetic ablation of epidermal EGFR reveals the dynamicorigin of adverse effects of anti-EGFR therapy［J］.Sci Transl Med,2013,5(199):199ral10.
［62］MASCIA F,MARIANI V,GIROLOMONI G,et al.Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation［J］.Am J Pathol,2003,163(1):303-312.
［63］WAN L,WANG Y,TANG Y,et al.Gefitinib induced cutaneous toxicities in brown norway rats are associated with macrophage infiltration［J］.Inflammation,2020,43(6):2137-2146.
［64］SHEPHERDFA,PEREIRA JR,CIULEANU T,et al.Erlotinib in previously treated non-small-cell lung cancer［J］.New Engl J Med,2005,353(2):123-126.
［65］CHO JY,CHANG HJ,LEE SK,et al.Amelioration of dextran sulfate sodium-induced colitis in mice by oral administration of beta-caryophyllene,a sesquiterpene［J］.Life Sci,2007,80(10):932-939.
［66］LIU M,NIU W,OU L.B-Caryophyllene ameliorates the mycoplasmal pneumonia through the inhibition of NF-κB signal transduction in mice［J］.Saudi J Biol Sci,2021,28(8):4240-4246.
［67］CYPHERT TJ,MORRIS RT,HOUSE LM,et al.NF-κB-dependent airway inflammation triggers systemic insulin resistance［J］.Am J Physiol Regul Integr Comp Physiol,2015,309(9):R1144-R1152.
［68］BLAKELY CM,PAZARENTZOS E,OLIVAS V,et al.NF-κB activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer［J］.Cell Rep,2015,11(1):98-110.
［69］HARDER J,BARTELS J,CHRISTOPHERS E,et al.A peptide antibiotic from human skin［J］.Nature,1997,387(6636):861.
［70］MAJHI RK,MOHANTY S,KHAN MI,et al.Ag@ZnO nanoparticles induce antimicrobial peptides and promote migration and antibacterial activity of keratinocytes［J］.ACS Infect Dis,2021,7(8):2068-2072.
［71］SCHRODER JM,HARDER J.Antimicrobial skin peptides and proteins［J］.Cell Mol Life Sci,2006,63(4):469-486.
［72］KIM JM,JI JH,KIM YS,et al.rhEGF treatment improves EGFR inhbitor-induced skin barrier and immune defects［J］.Cancers,2020,12(11):3120.
［73］SCHNEIDER JJ,UNHOLZER A,SCHALLER M,et al.Human defensins［J］.Journal of Molecular Medicine,2005,83(8):587-595.
［74］FERRIS LK,MBURU YK,MATHERS AR,et al.Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells:an antimicrobial peptide that functions as an endogenous adjuvant ［J］.J Invest Dermatol,2013,133(2):460-468.
［75］NIYONSABA F,USHIO H,NAKANO N,et al.Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration,proliferation and production of proinflammatory cytokines and chemokines［J］.J Investig Dermatol,2007,127:594-604.
［76］许丽君,张瑞,董春明.抗菌肽LL-37研究进展［J］.军事医学,2022,46(7):7. XU LJ,ZHANG R,DONG CM.Research progress of antimicrobial peptide LL-37［J］.Military Medicine,2022,46(7):7.
［77］RADEMACHER F,SCHEEL A,GLASER R,et al.Inhibition of RNase 7 by RNase inhibitor promotes inflammation and Staphylococcus aureus growth:Implications for atopic dermatitis［J］.Allergy,2024,79(6):1573-1583.
［78］ARNAUD T,RODRIGUES-LIMA F,VIGUIER M,et al.Interplay between EGFR,E-cadherin,and PTP1B in epidermal homeostasis［J］.Tissue Barriers,2023,11(3):2104085.
［79］PEUVREL L,BACHMEYER C,REGUIAI Z,et al.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors［J］.Support Care Cancer,2012,20(5):909-921.
［80］HARDING CLIVE R.The stratum corneum:structure and function in health and disease［J］.Dermatol Ther,2004,17 Suppl 1:6-15.
［81］EILERS RE,GANDHI M,PATEL JD,et al.Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy［J］.J Natl Cancer Inst,2010,102(1):47-53.
［82］CUI L,JIA Y,CHENG ZW,et al.Advancements in the maintenance of skin barrier/skinlipid composition and the involvement of metabolic enzymes［J］.Journal of cosmeticdermatology,2016,15(4):549-558.
［83］OH JH,HUR W,LI N,et al.Effects of the epidermal growth factor receptor inhibitor,gefitinib,on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes［J］.Exp Dermatol,2022,31(6):918-927.
［84］MA T,HARA M,SOUGRAT R,et al.Impaired stratum corneum hydration in mice lacking epidermal water channel aquaporin-3［J］.J Biol Chem,2002,277(19):17147-17153.
［85］IKARASHI N,KANEKO M,WATANABE T,et al.Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib induces dry skin via decreased in aquaporin-3 expression［J］.Biomolecules,2020,10(4):545.
［86］HARA-CHIKUMA M,VERKMAN AS.Aquaporin-3 functions as a glycerol transporter in mammalian skin［J］.Biol Cell,2005,97(7):479-486.
［87］HARA-CHIKUMA M,VERKMAN AS.Roles of aquaporin-3 in the epidermis［J］.J Invest Dermatol,2008,128(9):2145-2151.
［88］CALIFANO R,TARIQ N,COMPTON S,et al.Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK［J］.Drugs,2015,75(12):1335-1348.
［89］KAWASHIMA M,KIYOHARA Y,YAMAZAKI N,et al.The management of molecular-targeted cancer drug-induced skin toxicity:a report from consensus conference held with volunteer dermatologists and medical oncologists［J］.Rinsyo Iyaku,2014,30:975-981.
［90］CALIFANO R,TARIQ N,COMPTON S,et al.Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK［J］.Drugs,2015,75:1335-1348.
［91］GUTZMER R,BECKER JC,ENK A,et al.Management of cutaneous side effects of EGFR inhibitors:recommendations from a German expert panel for the primary treating physician［J］.J der Deutschen Dermatol Gesellschaft,2011,9:195-202.
［92］HIRSH V.Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer［J］.Curr Oncol,2011,18:126-138.
［93］LACOUTURE M,ANADKAT M,BENSADOUN RJ,et al.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities［J］.Support Care Cancer,2011,19:1079-1095.
［94］POTTHOFF K,HOFHEINZ R,HASSEL JC,et al.Interdisciplinary management of EGFR-inhibitor-induced skin reactions:a German expert opinion［J］.Ann Oncol,2011,22:524-535.
［95］THATCHER N,NICOLSON M,GROVES RW,et al.Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K［J］.Oncologist,2009,14:840-847.
［96］上海市医学会皮肤性病学分会,上海市医学会肿瘤靶分子专科分会.抗肿瘤药物相关皮肤不良反应管理专家共识［J］.中华皮肤科杂志,2023,56(10):907-919. Shanghai Municipal Medical Association Dermatology and Venereology Branch,Shanghai Municipal Medical Association Tumour Targeted Molecular Branch.Expert consensus on the management of cutaneous adverse reactions associated with antineoplastic drugs［J］.Chinese Journal of Dermatology,2023,56(10):907-919.
［97］LACOUTURE ME,SIBAUD V,GERBER PA,et al.Prevention and management of dermatological toxicities related toanticancer agents:ESMO clinical practice guidelines［J］.Ann Oncol,2021,32(2):157-170.
［98］AGIRGOL S,AYTEMEL C,PILANCI KN.Dermatological side effects of targeted antineoplastic therapies:a prospective study［J］.Cutan Ocul Toxicol,2020,39(4):380-384.
［99］BALAGULA E,LACOUTURE ME.Dermatologic toxicities of targeted anticancer therapies［J］.J Support Oncol,2010,8(4):149-161.
［100］MELOSKY B,HIRSH V.Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs［J］.Front Oncol,2014,4:238.
［101］LACOUTURE ME,SCHADENDORF D,CHU CY,et al.Dermatologic adverse events associated with afatinib:an oral ErbB family blocker［J］.Expert Rev Anticancer Ther,2013,13(6):721-728.
［102］陈新谦,金有豫,汤光,等.新编药物学［M］.第17版.北京:人民卫生出版社,2016:673,678,687. CHEN XQ,JIN YY,TANG G,et al.New pharmacy［M］.17th ed.Beijing:People's Health Publishing House,2016:673,678,687.
［103］张可心,贾文静,崔佳文,等.第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展［J］.中国临床药理学与治疗学,2022,27(9):1016-1030. ZHANG KX,JIA WJ,CUI JW,et al.Application and research progress of third-generation EGFR tyrosine kinase inhibitors in the clinical treatment of non-small cell lung cancer［J］.Chinese Clinical Pharmacology and Therapeutics,2022,27(9):1016-1030.
［104］BOUSTANY Y,LARAQUI A,EL RHAFFOULI H,et al.Prevalence and patterns of EGFR mutations in non-small cell lung cancer in the Middle East and North Africa［J］.Cancer Control,2022,29:1-9.
［105］ROSELL R,MORAN T,QUERALT C,et al.Screening for epidermal growth factor receptor mutations in lung cancer［J］.N Engl J Med,2009,361(10):958-967.

Memo

Memo:
国家中医药管理局基本中医药循证能力建设项目（编号：2019XZZX-JB004）；铁道部专项课题（编号：J2020Z606）；北京市中医药科技发展资金项目（编号：JJ-2020-57）
Last Update: 1900-01-01